3 Einträge gefunden

1. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

   1. Weisel, Katja
   2. Martin, Thomas
   3. Krishnan, Amrita
   4. Jagannath, Sundar
   5. Londhe, Anil
   6. Nair, Sandhya
   7. Diels, Joris

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)

   1. Hillengass, Jens
   2. Cohen, Adam D
   3. Delforge, Michel
   4. Einsele, Hermann
   5. Goldschmidt, Hartmut
   6. Weisel, Katja
   7. Raab, Marc-Steffen

   2022 - Forschungsinformationssystem des UKE
3. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

   1. Weisel, Katja
   2. Krishnan, Amrita
   3. Schecter, Jordan M
   4. Vogel, Martin
   5. Jackson, Carolyn C
   6. Deraedt, William
   7. Yeh, Tzu-Min

   2022 - Forschungsinformationssystem des UKE - frei zugänglich